Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IMAGING TB

Financiado

Cerrado

Deciphering mycobacterial subversion of early steps of adaptive immunity in vivo...

Deciphering mycobacterial subversion of early steps of adaptive immunity in vivo A new approach to solve an old problem "Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis (Mtb) and currently one third of the world’s population is latently infected with Mtb, in spite of the existence of a vaccine. This scenario is in part due to Mt... ver más

31/03/2014

CNRS

269K€

Presupuesto del proyecto: 269K€

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-03-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

CNRS

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TBVAC-HORIZON Improving understanding of lung immunity in tuberculosis to... 7M€ Cerrado

HOMITB Host and microbial molecular dissection of pathogenesis and... 4M€ Cerrado

MART Mucosal antibody and B cell responses during Tuberculosis 203K€ Cerrado

ECOEVODRTB Linking within host and between host evolution of multidrug... 3M€ Cerrado

Slow growth Deciphering the molecular mechanism s behind the evolution... 185K€ Cerrado

AUTOPHAGTUBERCULOSIS MOLECULAR MECHANISMS OF AUTOPHAGY REGULATION IN TUBERCULOSIS 100K€ Cerrado

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 269K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis (Mtb) and currently one third of the world’s population is latently infected with Mtb, in spite of the existence of a vaccine. This scenario is in part due to Mtb’s ability to adapt to current treatments, e.g. development of multi-resistance to antibiotics. However we also lack a proper understanding of the immunological mechanisms subverted by Mtb to establish a chronic infection and the reasons for the failure of the current vaccine to provide protection. Hence, new cross-disciplinary approaches are required to identify at what level Mtb virulence factors or the current vaccine strain prevent the induction of a protective immune response. Here we will identify the mechanisms by which mycobacterium strains subvert T cell immunity that is critical for the protection from fatal infection. We will do this in the context of an infection with virulent Mtb and vaccination with the current vaccine strain (BCG) or a new attenuated Mtb strain that is a promising candidate for a new TB vaccine. To this purpose we will investigate a critical step for the initiation of T cell immunity against mycobacteria, the migration of infected dendritic cells to the draining lymph node. Our approach will make use of unique tools to gain new insights into the interaction between host factors and mycobacteria virulence factors. These include novel intravital multiphoton microscopy studies of the infectious process in the lung and cross-disciplinary approaches such as a high-throughput screen of a library of Mtb mutants for regulators of dendritic cell function. This research proposal will benefit from the unique synergy between the expertise in mycobacterium’s biology of the host institution and my immunological expertise of T cell immunity. Therefore, we foresee making significant contributions that will be instrumental for the development of new vaccines and more efficient treatments of TB."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores